InnovationRx: A New Blood Thinner On The Horizon
InnovationRx is your weekly digest of healthcare news. Sign up!
Source: forbes.com
📰 Dan Bloomfield News
Dan Bloomfield News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dan Bloomfield. Real-time updates on events, politics, business and more.
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 12, 2023--
Source: eagletribune.com
Trial Halted for Bleeding Reduction With Abelacimab in AF
The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.
United States Dan Bloomfield Marc Sabatine National Blood Clot Alliance Drug Administration Anthos Therapeutics
Source: medscape.com
Anthos Stops Mid-Stage Atrial Fibrillation Trial Due to 'Unprecedented' Efficacy
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.
United States Johnson Xarelto Dan Bloomfield Data Monitoring Committee Blackstone Life Sciences New England Journal
Source: biospace.com
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC
Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC
Source: dicardiology.com
Abelacimab Demonstrates "Overwhelming" Efficacy vs Rivaroxaban in Phase 2b Trial
Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
Marcs Sabatine Dan Bloomfield Lewis Dexter Study Group International Society On Thrombosis Data Monitoring Committee
Source: hcplive.com
Regulatory Authorities in China and Japan Approve Clinical
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated ...
Source: globenewswire.com
Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib
Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Source: dicardiology.com
Anthos receives FDA's Fast Track designation for a drug candidate targeting patients with AFib
This is the second Fast Track designation Anthos has received for abelacimab in less than two months. The therapeutic is also the first Factor XI inhibitor to start enrolling patients in Phase 3 trials.
United Kingdom United States Dan Bloomfield Drug Administration Bristol Myers Squibb Anthos Therapeutics
Source: medcitynews.com